지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.5
- 수록면
- 202 - 218 (17page)
- DOI
- https://doi.org/10.4111/icu.20230006
이용수
초록· 키워드
오류제보하기
Bladder cancer ranks as the 10th most common cancer type globally, and muscle-invasive disease accounts for approximately 25% of newly diagnosed bladder cancers. Despite definitive treatment, 50% of patients with muscle-invasive bladder cancer (MIBC) develop metastasis within 2 years, leading to death. Perioperative systemic therapy is generally recommended to control local relapse or distant metastasis after surgical resection for patients with MIBC. Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the current standard treatment to improve oncologic control and survival outcomes. Adjuvant chemotherapy is recommended for patients with pathological T3-4 or positive lymph nodes after radical cystectomy if no neoadjuvant chemotherapy was given. Nonetheless, perioperative systemic therapy is not applied widely because of its toxicity, and less than 25% of patients receive cisplatin-based neoadjuvant chemotherapy. Therefore, the development of predictive biomarkers for neoadjuvant chemotherapy efficacy and alternative effective regimens for cisplatin-ineligible patients are important. Furthermore, recently, novel anticancer agents such as immune checkpoint inhibitors and antibody-drug conjugates have proven survival benefits in the metastatic setting, thereby expanding their therapeutic applications to the perioperative setting for non-metastatic MIBC. Herein, we discuss the current status and future perspectives of perioperative systemic strategies for MIBC.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
Investigative and Clinical Urology
2020 .01
-
Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
Investigative and Clinical Urology
2022 .03
-
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
Cancer Research and Treatment
2021 .10
-
The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
Cancer Research and Treatment
2022 .01
-
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines
Annals of Laboratory Medicine
2017 .07
-
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
Journal of Breast Cancer
2019 .01
-
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
Cancer Research and Treatment
2016 .01
-
Role of Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Research and Treatment
2023 .04
-
Diabetes is an Important Risk Factor for Metastasis in Non-Muscle-Invasive Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies
Cancer Research and Treatment
2024 .07
-
The Role of Neoadjuvant Chemotherapy in Patients with ER Positive and HER2 Negative Breast Cancer
대한외과학회 학술대회 초록집
2018 .11
-
Risk factors for failing to complete gemcitabine–cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients
Investigative and Clinical Urology
2024 .05
-
Options and Outcomes of Neoadjuvant Chemotherapy
대한외과학회 학술대회 초록집
2021 .11
-
The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
Cancer Research and Treatment
2022 .10
-
Recent Advances in the Neoadjuvant Treatment of Breast Cancer
Journal of Breast Cancer
2017 .01
-
Current Guideline and Future of Radiation Therapy after Neoadjuvant Chemotherapy and Surgery
대한외과학회 학술대회 초록집
2020 .11
-
Effect of Neoadjuvant Chemotherapy on Axillary Lymph Node Positivity and Numbers in Breast Cancer Cases
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Radiological response pattern and patient survival in patients undergoing neoadjuvant chemotherapy
대한외과학회 학술대회 초록집
2019 .10
-
선행항암화학요법을 받는 유방암 환자의 불안, 불확실성, 암 대처가 삶의 질에 미치는 영향
Asian Oncology Nursing
2022 .03
이 논문의 저자 정보
최근 본 자료
댓글(0)
0